Annals of clinical and laboratory science最新文献

{"title":"Rapid G6PD Screening Workflow for Timely Tumor Lysis Syndrome Management in Pediatric Oncology.","authors":"Nazmin Bithi, Mary C Shapiro, Rajaram Nagarajan, Sridevi Devaraj","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Glucose-6-phosphate dehydrogenase deficiency (G6PDD) poses significant safety concerns in pediatric oncology, particularly during tumor lysis syndrome (TLS) management where rasburicase may precipitate hemolysis or methemoglobinemia. Prior to this initiative, our institution relied on send-out quantitative G6PD testing with prolonged turnaround times (TAT), limiting timely clinical decision-making.</p><p><strong>Methods: </strong>A rapid, in-house qualitative G6PD screening assay with reflex quantitative testing for abnormal (\"Intermediate\" or \"Deficient\") results was implemented and incorporated into institutional TLS guidelines. Test utilization, TAT, and concordance between qualitative screening, quantitative enzyme activity, and World Health Organization (WHO) classification criteria were evaluated.</p><p><strong>Results: </strong>A total of 106 patients underwent qualitative G6PD screening between August 2025 and March 2026. Average TAT was less than 7 hours across all campuses. Screening classified 7 patients as \"Deficient,\" 56 as \"Intermediate,\" and 43 as \"Normal.\" 66 patients underwent quantitative testing, of whom 23 had enzyme activity below the age-specific reference range. These included all 7 patients classified as \"Deficient\" and 16 initially classified as \"Intermediate.\" However, only 1 patient met WHO criteria for clinically significant G6PD deficiency (<30% activity).</p><p><strong>Conclusion: </strong>Rapid G6PD screening supported timely TLS management. Reflex quantitative testing remains essential, as interpretation varies substantially between qualitative screening, quantitative reference intervals, and WHO activity-based criteria.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 4","pages":"406-413"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ERRATUM.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 4","pages":"523"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Investigation of Anti-A and/or Anti-B Titer Test Results among Blood Donors Using a Single-Dilution Method.","authors":"Mark H Yazer, Emilie A Jochumsen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated the proportion of high anti-A and/or anti-B titer blood donors at a large blood collector over >3 years.</p><p><strong>Methods: </strong>Donors of products that could be used in an ABO-plasma incompatible manner were titer tested. Low titer was defined as <100. The study period was January 27, 2020 through May 13, 2023.</p><p><strong>Results: </strong>A total of 11,145 unique donors made 30,035 titer tested donations. There were 843/11,145 (7.6%) donors who made at least one high titer donation. There were 106/167 (63.5%) donors who made a high titer donation on their first donation and subsequently made a low titer donation after a median (95% CI) of 116.5 days (89-160 days). The high titer rate for all donors varied from a low of ~2.8% in Q3 2020 to a high of ~5.9% in Q1 2022, with no clear seasonal periodicity among high titer donors. The majority of donors who made at least one high titer donation were group O (589/843, 69.9%). There was a slight female predominance among high titer donors along with a greater representation of younger donors compared to those who only made low titer donations.</p><p><strong>Conclusions: </strong>These results support titer testing of all donations because seasonal variation in the donor high titer rate was not demonstrated and many donors who initially tested above the 100 titer threshold subsequently tested below it, though the magnitude of titer change could not be determined with the single-dilution method used.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 4","pages":"387-394"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inherited Factor VII Deficiency Identified in a Patient with Acute Myeloid Leukemia: A Case Report.","authors":"Takho Kang, Kunye Kwak, Myung-Hyun Nam, Yunjung Cho, Yong Park, Jisook Yim","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Factor VII (FVII) deficiency is a clinical condition occasionally encountered in the evaluation of coagulopathy. Although acquired FVII deficiency has been documented in association with acute myeloid leukemia (AML), the coexistence of AML and inherited FVII deficiency has not been previously reported. Here, we present a case of inherited factor VII deficiency concurrently identified in a patient with acute myeloid leukemia, in which targeted <i>F7</i> gene sequencing identified compound heterozygosity for likely pathogenic variants. This case underscores that coagulopathy in patients with hematologic malignancies should not be reflexively attributed solely to acquired causes. Maintaining clinical suspicion for underlying inherited coagulation disorders is essential to prevent diagnostic oversights and to facilitate tailored management.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 4","pages":"500-504"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma and Atopy Prevalence in Perinatally HIV-Exposed but Uninfected Children.","authors":"Sabah N Islam, Stephan Kohlhoff, Rauno Joks, Tamar A Smith-Norowitz","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Increased atopy prevalence has been reported in human immunodeficiency virus (HIV)-infected adults. Previous studies in our laboratory demonstrated that there was no increased prevalence of atopy in perinatally HIV-infected children compared with the general population. This has not been studied in uninfected children. This study investigates the prevalence of asthma and atopy (i.e., allergic rhinitis, atopic dermatitis, urticaria, general allergies) in perinatally HIV-exposed, uninfected compared with HIV-unexposed, uninfected children.</p><p><strong>Methods: </strong>Retrospective chart review identified patients (F/M, 0 to 21 y/o) seen at an academic center between the years 2005-2025. Patients were either perinatally HIV-exposed but uninfected (N=62) or control group (N=60) (HIV-unexposed, uninfected). Using SAS v9.4.3, prevalence of asthma/atopy by HIV exposure was analyzed.</p><p><strong>Results: </strong>Prevalence of atopy was higher in perinatally HIV-exposed, uninfected versus HIV-unexposed, uninfected children (<i>P</i>=<0.0001). Asthma prevalence was higher in HIV-unexposed, uninfected children compared with controls (<i>P</i>=0.0198). Of asthmatic children, the prevalence of atopy was higher in HIV-exposed, uninfected children (<i>P</i>=0.0030) (Fisher's Exact test).</p><p><strong>Conclusions: </strong>The increased prevalence of allergy and atopy in perinatally HIV-exposed, uninfected children may be linked to dysregulated inflammatory processes in association with intrauterine/perinatal HIV exposure.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 4","pages":"414-419"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WWOX Suppresses Gastric Cancer Cell Proliferation, Migration, and EMT by Negatively Regulating the Wnt/β-Catenin Signaling Pathway.","authors":"Kelong Tao, Bowen Jin, Chenyu Chen, Songhe Ping, Meng He, Guangen Xu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to unveil whether WWOX modulates epithelial-mesenchymal transition (EMT), proliferation, and invasive capacity of gastric cancer (GC) cells via regulating the Wnt/β-catenin signaling pathway.</p><p><strong>Methods: </strong>WWOX expression in GC cell lines was assessed by Western blotting (WB) and immunofluorescence. Gain- and loss-of-function approaches were employed by establishing stable WWOX-overexpressing (oe WWOX) MKN28 and HGC27 cell lines and performing siRNA-mediated WWOX (si WWOX) knockdown in the same cell lines. Cell proliferation and invasion were evaluated using CCK-8 and Transwell assays, and EMT-related protein expression was examined by WB. To determine whether WWOX functions through the Wnt/β-catenin pathway, oe WWOX cells were treated with the pathway agonist SKL2001, and WWOX-silenced cells were treated with the β-catenin inhibitor XAV939; β-catenin levels in whole-cell lysates, as well as nuclear and cytoplasmic fractions, were analyzed by WB. The <i>in vivo</i> effects of WWOX overexpression and knockdown were assessed using subcutaneous xenograft models in nude mice.</p><p><strong>Results: </strong>WWOX expression was markedly reduced in GC cells. WWOX overexpression significantly suppressed proliferation, invasion, and EMT, accompanied by decreased β-catenin levels in total cell lysates as well as in nuclear and cytoplasmic fractions. Conversely, WWOX knockdown promoted malignant phenotypes and increased β-catenin expression in both fractions. SKL2001 treatment effectively counteracted the tumor-suppressive effects of WWOX overexpression, whereas XAV939 treatment reversed the tumor-promoting effects induced by WWOX knockdown. <i>In vivo</i>, WWOX overexpression suppressed tumor growth and reversed EMT, while WWOX knockdown promoted tumor growth and EMT progression; these changes were associated with reciprocal alterations in WWOX and β-catenin expression in tumor tissues.</p><p><strong>Conclusion: </strong>WWOX suppresses GC cell proliferation, invasion, and EMT both <i>in vitro</i> and <i>in vivo</i> by negatively regulating the Wnt/β-catenin signaling pathway. These findings provide a mechanistic basis for targeting the WWOX/Wnt/β-catenin axis as a potential therapeutic strategy for GC.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 4","pages":"473-481"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finerenone Regulates Macrophage-Tubular Crosstalk in Diabetic Nephropathy via the AMPK/PKM2 Pathway.","authors":"Jimei Tang, Lifei Zhu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To clarify how finerenone (FIN) regulates macrophage-renal tubular crosstalk in diabetic nephropathy (DN) via the AMPK/PKM2 pathway.</p><p><strong>Methods: </strong>Diabetes was experimentally induced in C57BL/6J mice via intraperitoneal injection of streptozotocin after high-fat diet feeding for eight weeks. FIN treatment was initiated five days after diabetes induction and continued for 12 weeks. DN in mice was evaluated by measuring blood glucose, urea nitrogen, creatinine, and urinary microalbumin, together with histopathological evaluation. Mouse BMDMs were exposed to high glucose (HG) and treated with FIN and the AMPK inhibitor compound C (CC). Polarization of BMDMs was assessed by immunofluorescence and western blot. A co-culture system was established by treating mouse renal tubular epithelial cells (RTECs) with conditioned medium (CM) from BMDMs. The viability of mouse RTECs, the expression levels of NGAL and KIM-1, and apoptosis-related proteins in mouse RTECs were measured.</p><p><strong>Results: </strong>FIN alleviated renal injury in mice with DN. Experimental evidence indicated that FIN inhibited macrophage M1 polarization and promoted AMPK/PKM2 pathway activation. In HG-stimulated FIN-treated BMDMs, CC significantly suppressed the activity of the AMPK/PKM2 pathway and promoted M1 polarization of BMDMs. In the co-culture system, the CM from HG-treated BMDMs inhibited mouse RTECs viability, increased the expression of KIM-1 and NGAL proteins, and induced apoptosis. In contrast, the CM from HG- and FIN-treated BMDMs enhanced mouse RTECs viability, reduced the expression of KIM-1 and NGAL proteins, and suppressed apoptosis.</p><p><strong>Conclusion: </strong>FIN ameliorates DN by regulating the AMPK/PKM2 pathway to influence macrophage polarization and attenuate RTEC injury.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 4","pages":"432-443"},"PeriodicalIF":0.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information About The Association of Clinical Scientists.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 3","pages":"384"},"PeriodicalIF":0.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148576808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of <i>Chlamydia trachomatis</i> Pgp3 Antibody in Human Sera.","authors":"Tamar A Smith-Norowitz, Sara Abdelrahaman, Sabah N Islam, Haram Abdelmajid, Rauno Joks, Margaret R Hammerschlag, Stephan A Kohlhoff","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong><i>Chlamydia trachomatis</i> is the most common bacterial sexually transmitted infection (STI) worldwide. Genital infection with <i>C. trachomatis</i> in women can cause ascending infection leading to pelvic inflammatory disease. Studies have suggested that the Pgp3 protein encoded by <i>C. trachomatis</i> plasmid may contribute to long term inflammatory complications of <i>C. trachomatis</i> infection (tubal factor infertility). This study assessed <i>C. trachomatis</i>-specific Pgp3 IgG antibody levels in sera from adolescents and young adults in an inner-city population in New York.</p><p><strong>Methods: </strong>Blood was obtained from patients seen in a primary care setting as part of a <i>C. trachomatis</i> seroepidemiology study. Serum samples were selected based on <i>C. trachomatis</i> IgG status (anti-MOMP, Labsystems). <i>C. trachomatis</i> anti-Pgp3 antibodies were assayed in sera from both <i>C. trachomatis</i> IgG positive and negative subjects.</p><p><strong>Results: </strong>We identified 39 participants, 16-20 y/o (mean age 18±1.2). The number of <i>C. trachomatis</i> IgG positive or negative subjects was 24 and 15, respectively; of the IgG positive subjects, 15% were males, and 85% were females. The mean distribution (OD value) of Pgp3 antibody responses in IgG positive versus negative subjects was 1.03±0.32 and 1.08±0.31 respectively; <i>P</i>=0.7833. The mean difference for Pgp3 responses was 0.0507±0.31, <i>P</i>=0.6266 (two sample <i>t</i>-test).</p><p><strong>Conclusion: </strong><i>C. trachomatis</i> Pgp3 antibody responses were similar in <i>C. trachomatis</i> anti-MOMP IgG positive and negative subjects.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 3","pages":"265-269"},"PeriodicalIF":0.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148576781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance Evaluation of the AccuPower Hepatitis C Virus Quant Assay Compared to the Cobas 6800 Hepatitis C Virus Assay.","authors":"Byoung-Sun Mun, Qute Choi, Hyun-Jin Kim, Jung Yoon, Soo-Young Yoon","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Hepatitis C virus (HCV) causes chronic liver disease, affecting 58 million people globally. Although antibody testing is cost-effective for screening, nucleic acid testing (NAT) enables early detection and treatment monitoring. Automated systems improve HCV RNA quantification efficiency. This study evaluates the lyophilized AccuPower HCV Quant Kit on ExiStation FA, comparing its performance with Cobas 6800 for viral load testing.</p><p><strong>Methods: </strong>AccuPower kit was evaluated on ExiStation FA96. Precision, linearity, limit of detection (LOD), and lower limit of quantitation (LLOQ) were assessed using World Health Organization (WHO) standards. Agreement and correlation were evaluated by comparing results with the Cobas HCV test using 368 clinical serum samples.</p><p><strong>Results: </strong>The assay demonstrated intra- and inter-assay variability lower than CVs of 5% across evaluated concentrations and showed strong linearity with expected concentration (R²=0.99). The LOD and LLOQ of the assay were 3.37 IU/mL and 7.50 IU/mL, respectively. Clinical comparison showed almost perfect agreement (κ=0.98) and correlation (r=0.971). Bland-Altman analysis revealed minimal bias (mean bias of -0.27±0.67 log₁₀ IU/mL).</p><p><strong>Conclusions: </strong>The AccuPower HCV Quant Kit used with the ExiStation FA system provides reliable and accurate HCV RNA quantification with operational advantages, supporting its suitability for both HCV screening and clinical management.</p>","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"56 3","pages":"279-289"},"PeriodicalIF":0.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148576914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}